

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: [AgraFlora Organics International Inc.](#) (the "Issuer" or the "Company" or "AgraFlora").

Trading Symbol: [AGRA](#)

Number of Outstanding Listed Securities: [1,927,234,778 as at March 31, 2021](#)

Date: [April 7, 2021](#)

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

[.The Issuer confirms that the impact of COVID-19 on its business and operations has been minimal. The Issuer is continuing to move forward with obtaining its license to cultivate cannabis from Health Canada and is continuing with building](#)

out the Issuer's 2.2 million square foot Delta Greenhouse Facility (the "Delta Facility")

2. Provide a general overview and discussion of the activities of management.

During the month of **March 2021**, the Issuer:

- Announced the resignation of Brandon Boddy as Chief Executive Officer, Chairman, Corporate Secretary, and Director.
 - Appointed Elise Coppens as Chief Executive Officer and Director.
 - Engaged Meadowbank Strategic Partners Inc. to provide investor relations, capital markets, and corporate development advisory services.
 - Announced the resignation of Christopher Hornung as Director.
 - Held their Annual General Meeting on March 26, 2021 whereas Brian O'Neill, Jerry Habuda, and Joseph Perino were re-appointed as directors.
 - Re-appointed Elise Coppens as a Director (as the company had previously received the resignation of Brandon Boddy after the date on which the information circular was published, Mr. Boddy was not re-elected at the AGM, and Ms. Coppens was subsequently re-elected to fill the vacancy).
 - Tended to general management and administrative matters.
3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Not applicable for the month of **March 2021**.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Not applicable for the month of **March 2021**.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

On **March 8, 2021**, the issuer announced that it had engaged Meadowbank Strategic Partners Inc. ("**Meadowbank**"), a corporate consultancy based in Calgary, Alberta, to provide investor relations, capital markets and corporate

development advisory services for an initial term of three months, pursuant to the terms of the consulting agreement entered into between the Company and Meadowbank (the "**Agreement**"). Certain functions and aspects of Meadowbank's services are anticipated to include "investor relations activities" under the policies of the CSE and applicable securities laws. Under the terms of the Agreement, Meadowbank will be paid a minimum of \$3,500 plus GST in cash per month, or a minimum of \$10,500 plus GST in aggregate, for its services. Meadowbank will not receive any securities in the capital of the Company as compensation for its services. Neither Meadowbank nor its principal currently own any securities of AgraFlora, however, Meadowbank, its principal and its affiliates may acquire or be awarded an interest in the securities of the Company at a future time. Meadowbank and AgraFlora are unrelated and unaffiliated entities.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Not applicable for the month of **March 2021**.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Not applicable for the month of **March 2021**.

8. Describe the acquisition of new customers or loss of customers.

Not applicable for the month of **March 2021**.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

Not applicable for the month of **March 2021**.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

Not applicable for the month of **March 2021**.

11. Report on any labour disputes and resolutions of those disputes if applicable.

Not applicable for the month of **March 2021**.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal

parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Not applicable for the month of **March 2021**.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Not applicable for the month of **March 2021**.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds
Common Shares	10,000,000	Issued pursuant to a three corner amalgamation ⁽¹⁾	N/A
Common Shares	89,512,328	Issued pursuant to the conversion of convertible debentures ⁽²⁾	N/A

Notes: Please refer to Section 11 of this form 7 for further information on the notes below:

- (1) Common Shares were issued at a price of \$0.03 per share for a total consideration of \$300,000, pursuant to a three corner amalgamation.
- (2) Common shares issued pursuant to the conversion of the Company's 10.00% Senior Unsecured Convertible Debentures.

15. Provide details of any loans to or by Related Persons.

Not applicable for the month of **March 2021**.

16. Provide details of any changes in directors, officers or committee members.

On **March 8, 2021**, the Issuer announced the resignation of Brandon Boddy as Chief Executive Officer, Chairman, Corporate Secretary, and Director, and the Issuer appointed Elise Coppens as Chief Executive Officer and Director.

On **March 10, 2021**, the Issuer announced the resignation of Christopher Hornung as Director.

At the issuer's AGM that took place on **March 26, 2021**, Brian O'Neill, Jerry Habuda, and Joseph Perino were re-appointed as directors. Subsequent to the AGM, the Issuer re-appointed Elise Coppens as a Director (as the company had previously received the resignation of Brandon Boddy after the date on which the information circular was published, Mr. Boddy was not re-elected at the AGM, and Ms. Coppens was subsequently re-elected to fill the vacancy).

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The trends and risks which are likely to impact the Issuer are detailed in the Issuer's Management Discussion and Analysis dated November 30, 2020 (the "MD&A"). The MD&A is available on the Issuer's SEDAR profile at

www.sedar.com and on the Issuer's disclosure hall with the CSE at www.thecse.com.

Additional trends that are likely to impact the Issuer include:

COVID-19

The outbreak of the coronavirus ("COVID-19") pandemic has impacted the Issuer's plans and activities. The Issuer may face disruption to operations, supply chain delays, travel and trade restrictions and impact on economic activity in affected countries or regions can be expected and can be difficult to quantify. Such pandemics or diseases represent a serious threat to maintaining a skilled workforce industry and could be a major health-care challenge for the Issuer. There can be no assurance that the Issuer's personnel will not be impacted by these pandemic diseases and ultimately that the Issuer would see its workforce productivity reduced or incur increased medical costs/insurance premiums as a result of these health risks. In addition, the COVID-19 pandemic has created a dramatic slowdown in the global economy. The duration of the COVID-19 outbreak and the resultant travel restrictions, social distancing, Government response actions, business closures and business disruptions, can all have an impact on the Issuer's operations and access to capital. There can be no assurance that the Issuer will not be impacted by adverse consequences that be brought about by the COVID-19 pandemic on global financial markets reduce resource prices, share prices and financial liquidity and thereby that severely limit the financing capital available.

[the balance of this page has been intentionally left blank]

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated [April 7, 2021](#)

[Elise Coppens](#)
Name of Director or Senior
Officer

["Elise Coppens"](#)
Signature

[CEO & Director](#)
Official Capacity

Issuer Details Name of Issuer	For Month End	Date of Report YY/MM/D
AgraFlora Organics International Inc.	March 2021	21/04/07
Issuer Address Suite 810 - 789 West Pender Street		
City/Province/Postal Code Vancouver, British Columbia, V6C 1H2	Issuer Fax No. 604-687-3141	Issuer Telephone No. 604-687-2038
Contact Name Elise Coppens	Contact Position CEO & Director	Contact Telephone No. 604-687-2038